Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: mCC Clear all
Recruiting Phase 1 Interventional

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

NCT06940440
View directory record Official record
Conditions
Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
IFx-Hu2.0, Pembrolizumab
Drug
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 2, 2026, 4:36 AM EDT
Terminated Phase 2 Interventional Results available

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

NCT02465957
View directory record Official record
Conditions
Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Interventions
aNK (NK-92), aNK (NK-92) + N-803
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 2, 2026, 4:36 AM EDT
Not listed Phase 1Phase 2 Interventional

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

NCT03787602
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
KRT-232, Avelumab
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib

NCT01645085
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MCC-based 13% drug loaded tablets, Mannitol-based 38% drug-loaded tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 2, 2026, 4:36 AM EDT
Suspended Phase 2 Interventional

Reducing Frailty for Older Cancer Survivors Using Supplements II

NCT06068543
View directory record Official record
Conditions
Frailty, Inflammation
Interventions
Epigallocatechin-3-Gallate (EGCG), Microcrystalline cellulose (MCC), Ascorbic Acid (Vitamin C)
Drug · Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 2, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional

Adaptation and Examination of a Trauma-informed Intervention for Pregnant Veterans

NCT06906185
View directory record Official record
Conditions
Trauma-related Mental Health Symptoms
Interventions
Calm Moms-V, Care As Usual
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

NCT00078013
View directory record Official record
Conditions
Myocardial Infarction
Interventions
MCC-135
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

NCT00934856
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Pertuzumab, Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Absorptive Clearance in the Cystic Fibrosis Airway

NCT00541190
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 2, 2026, 4:36 AM EDT
Completed No phase listed Observational Results available

A Study to Explore the Utility of Fractional Exhaled Nitric Oxide (FeNO) Compared With Methacholine Challenge (MCC) Testing in the Assessment of Patients With Suspected But Undiagnosed Asthma

NCT01648920
View directory record Official record
Conditions
Asthma
Interventions
NIOX MINO® Instrument (09-1100)
Device
Lead sponsor
Aerocrine AB
Industry
Eligibility
7 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Blue Bell, Pennsylvania • Collegeville, Pennsylvania • Doylestown, Pennsylvania + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 2, 2026, 4:36 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Evaluation of a Home Visiting Program for First Time Parents

NCT00579449
View directory record Official record
Conditions
Child Abuse
Interventions
Healthy Families Durham, Yearly Checkup
Behavioral
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 2, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

Further MT for Antibiotic-Resistant Bacterial Colonization

NCT05835206
View directory record Official record
Conditions
Intestinal Multi-drug Resistant Organism Colonization
Interventions
Microbiome Therapeutic, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 1 Interventional Results available

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

NCT03364348
View directory record Official record
Conditions
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine
Drug
Lead sponsor
George W. Sledge Jr.
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 2, 2026, 4:36 AM EDT
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 2, 2026, 4:36 AM EDT
Withdrawn Phase 2 Interventional

Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias

NCT03384095
View directory record Official record
Conditions
Breast Neoplasm Female, Arthralgia
Interventions
Hyaluronic Acid (HA), Placebo
Drug · Other
Lead sponsor
Erin Newton
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

NCT02267603
View directory record Official record
Conditions
Recurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7, Stage IIIA Merkel Cell Carcinoma AJCC v7, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Technology Enhanced Family Treatment

NCT03913013
View directory record Official record
Conditions
Mood Disorders, Bipolar Disorder, Major Depression
Interventions
Family-Focused Treatment with MCC App
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 1 Interventional

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

NCT02141191
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled hypertonic saline (7%)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Shared Decision Making About Medication Use for People With Multiple Health Problems

NCT05156073
View directory record Official record
Conditions
Polypharmacy, Dementia, Multiple Chronic Conditions, Deprescribing, Mild Cognitive Impairment
Interventions
Educational Materials
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Not applicable Interventional Results available

Time Restricted Eating for Weight Loss Maintenance

NCT05742165
View directory record Official record
Conditions
Obesity
Interventions
Time Restricted Eating (TRE)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 4:36 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

NCT06939036
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Interventions
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Drug
Lead sponsor
Ariceum Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Miami, Florida • Louisville, Kentucky • Glen Burnie, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 2, 2026, 4:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

NCT00875979
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 2, 2026, 4:36 AM EDT
Completed No phase listed Observational

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

NCT00368446
View directory record Official record
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 2, 2026, 4:36 AM EDT